428 results about "Thymus Glands" patented technology

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and / or experimental purpose.

This invention provides a nucleotide analogue comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3′-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analogue.

The invention relates to a method for obtaining thymosins and / or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and / or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product.

The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signalling is interrupted or ablated in the patient by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention discloses lymphocyte antigen epitope peptides and application thereof, belongs to the fields of medical immunology and infectious diseases, and particularly relates to 164 thymus dependent lymphocyte antigen epitope peptides of five proteins of SARS-CoV-2 and application thereof. The antigen epitope peptides can be presented by HLA-A molecules to stimulate activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted. The antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection, and have a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention provides a thymalfasin sustained-release microsphere preparation and a preparation method thereof. The thymalfasin sustained-release microsphere preparation comprises the following components in percentage by weight: 0.1 to 10 percent of thymalfasin, and 85 to 99 percent of poly(glycolide-co-lactide), wherein the poly(glycolide-co-lactide) is copolymer of glycolide and lactide, the ratio of the glycolide to the lactide is (25:75)-(75:25), the molecular weight of the poly(glycolide-co-lactide) is between 5,000 and 35,000 dalton, and the intrinsic viscosity is between 0.1 and 0.5dL / g. The pH value of the external water phase of the thymalfasin sustained-release microsphere preparation is between 3.0 and 5.0, and can be regulated by adopting acetic acid, hydrochloric acid, sulfuric acid and the like. The inventor discovers that by controlling the pH value of the external water phase, the stability of the thymalfasin can be improved and the entrapment rate in a preparation process also can be improved, so that the drug-loading rate of sustained-release microspheres can be improved.

The invention relates to a composition of thymic peptide alpha 1 and thymopeptide-5 and a preparation method thereof. The compound preparation can be used for the treatment of chronic hepatitis B andvarious diseases with damaged immunological functions and the auxiliary treatment of tumours. The composition mainly comprises 0.1-10mg of thymic peptide alpha 1 and 0.1-100mg of thymopeptide-5. Simultaneously, proper auxiliary materials are added into the composition to prepare injection liquid or a freeze-drying medicament form. The composition prepared according to the proportion has obvious synergy action and can reach a better curative effect dose ratio for the treatment of the chronic hepatitis B and various diseases with damaged immunological functions and the auxiliary treatment of thetumours.

The invention discloses a medicament for treating geriatric disease, and at the medicament can be used for solving the technical problems of improving the functions of viscera, improving the immunity, invigorating qi and blood, and ensuring not to cause the body of middle-aged and aged people aiming at the geriatric disease. The technical scheme adopted by the invention is as follows: the medicament is characterized by comprising 1 to 5,000g of ants, 1 to 3,000g of glssy ganoderma, and 1 to 500g of pearl. Compared with the prior art, the unique broad-spectrum and immunity dual immunomodulatory action of ants are sufficiently played, the degraded thymus gland is promoted to proliferate, the weight is increased, the lymphocytes in the cortical area are increased, the functions of immunity center are activated, the leucocytes and lysozymes in the blood are increased, and the phagocytosis is improved. The medicament has the functions of nourishing kidney, tonifying spleen and dredging abdomen, tranquilizing by nourishing the heart and promoting blood circulation to remove meridian obstruction, so that the body is restored to a normal metabolizing state to comprehensively treat the geriatric disease. Therefore, the medicament achieves the aims of preventing and treating geriatric disease, delaying aging, improving wisdom and strengthening body, and protecting bodies of middle-aged and aged people from being hurt.

The invention relates to the field of biological monitoring, and specifically relates to a secondary antibody probe for a sandwich immune reaction by using an amperometric immunosensor, wherein, the secondary antibody probe is composed of calf thymus DNA molecular chains and nanospheres adhering to the calf thymus DNA molecular chains, and the surfaces of the nanospheres are covered by enzyme labeled antibody proteins while magnetic nanometer particles, which are formed by depositing a layer of amorphous zirconia on the surfaces of nanometer ferriferrous oxide particles, are filled in the nanospheres. The secondary antibody probe provided in the invention is suitable for measurring concentration of antigens by a sandwich immune reaction employing an amperometric immunosensor, and has the advantages of wide linear range of detection and low detection limits.

The invention provides a kit for detecting human immune ages and an application of the kit. Reagents in the kit comprise CD3, CD4, CD31 and CD45RA monoclonal antibodies which are four fluoresceins applicable to flow cytometers, and the colors of the four fluoresceins are different. The reagents in the kit comprise, in weight percent, 0.66-94.34% of fluorescent labeled CD3, 0.66-94.34% of fluorescent labeled CD4, 0.66-94.34% of fluorescent labeled CD31 and 0.66-94.34% of fluorescent labeled CD345RA. The kit is used for detecting recently outputted cell number of human thymuses, the immune agesof people are determined according to detection results of the recently outputted cell number of the human thymuses, and the immune ability of a human body is evaluated.

A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism.